Transcript : Intra-Cellular Therapies, Inc. - Special Call
Apr. 16
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Apr. 16
AQ
Transcript : Intra-Cellular Therapies, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Feb. 22
Transcript : Intra-Cellular Therapies, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM
Jan. 09
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
Dec. 05
AQ
Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Nov. 02
Transcript : Intra-Cellular Therapies, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:55 PM
23-09-12
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
23-09-11
AQ
Transcript : Intra-Cellular Therapies, Inc., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Transcript : Intra-Cellular Therapies, Inc., Q1 2023 Earnings Call, May 04, 2023
23-05-04
Transcript : Intra-Cellular Therapies, Inc. - Special Call
23-03-28
Transcript : Intra-Cellular Therapies, Inc., Q4 2022 Earnings Call, Mar 01, 2023
23-03-01
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
22-12-08
AQ
Transcript : Intra-Cellular Therapies, Inc., Q3 2022 Earnings Call, Nov 03, 2022
22-11-03
Transcript : Intra-Cellular Therapies, Inc., Q2 2022 Earnings Call, Aug 09, 2022
22-08-09
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
22-06-13
AQ
Transcript : Intra-Cellular Therapies, Inc., Q1 2022 Earnings Call, May 10, 2022
22-05-10
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA (lumateperone) for Specific Patient Populations
22-04-26
AQ
Intra Cellular Therapies : Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations - Form 8-K
22-04-25
PU
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
22-04-25
AQ
Transcript : Intra-Cellular Therapies, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 07:30 AM
22-01-10
Transcript : Intra-Cellular Therapies, Inc., Q3 2021 Earnings Call, Nov 09, 2021
21-11-09
Transcript : Intra-Cellular Therapies, Inc. - Special Call
21-10-20
Transcript : Intra-Cellular Therapies, Inc., Q2 2021 Earnings Call, Aug 09, 2021
21-08-09
Transcript : Intra-Cellular Therapies, Inc., Q1 2021 Earnings Call, May 10, 2021
21-05-10
Transcript : Intra-Cellular Therapies, Inc. - Special Call
21-05-04
Transcript : Intra-Cellular Therapies, Inc., Q4 2020 Earnings Call, Feb 25, 2021
21-02-25
Transcript : Intra-Cellular Therapies, Inc., Q3 2020 Earnings Call, Nov 09, 2020
20-11-09
Intra-Cellular Therapies, Inc. Announces Executive Changes
20-10-02
CI
Intra Cellular Therapies : Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
20-10-02
AQ
INTRA-CELLULAR THERAPIES, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
20-10-01
AQ
Intra-Cellular Therapies, Inc. Announces Executive Changes
20-10-01
CI
Intra Cellular Therapies : Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
20-10-01
AQ
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
20-10-01
GL
Transcript : Intra-Cellular Therapies, Inc. - Special Call
20-09-09
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
19-02-27
GL
Transcript : Intra-Cellular Therapies, Inc., Q3 2018 Earnings Call, Nov 07, 2018
18-11-07
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results
18-11-07
GL
Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
18-08-20
GL
Intra-Cellular Therapies Appoints Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
18-08-20
CI
